Clinical Trials Directory

Trials / Completed

CompletedNCT02226471

Serum CTRP3 and RBP4 Levels in Obesity and Hypertension

Status
Completed
Phase
Study type
Observational
Enrollment
2,000 (actual)
Sponsor
Third Military Medical University · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Accepted

Summary

Insulin resistance is closely correlated with obesity and cardiovascular disease. Adipokines may play important roles in the pathogenesis of obesity, which are a link between obesity and obesity-related disorders.C1q/TNF-related protein-3 (CTRP3) and retinol-binding protein 4 (RBP4) are novel adipokine that modulates the action of insulin in various diseases. This study addressed the relationship between CTRP3, RBP4 and IR in newly diagnosed obesity and essential hypertension.

Detailed description

Serum CTRP3 and RBP4, anthropometric and metabolic parameters were determined in 480 newly diagnosed obesity and essential hypertensive patients not taking anti-obese and antihypertensive medications and 66 normal weight (NW) and normotensive subjects. All subjects were divided into two groups depending on body mass index (BMI), including NW group and obesity group, and then four subgroups were divided according to obesity and hypertension, including NW-normal blood pressure subgroup (NW-NBP), NW-hypertension subgroup (NW-HTN), obese-normal blood pressure subgroup (OB-NBP), obese-hypertension subgroup (OB-HTN).

Conditions

Timeline

Start date
2012-03-01
Primary completion
2014-02-01
Completion
2014-02-01
First posted
2014-08-27
Last updated
2014-08-27

Source: ClinicalTrials.gov record NCT02226471. Inclusion in this directory is not an endorsement.